REVIEW

REVIEWED Recent insights into the implications of metabolism in plasmacytoid dendritic cell innate functions: Potential ways to control these functions [version 2; peer review: 3 approved]

Philippe Saas ¹, Alexis Varin¹, Sylvain Perruche¹, Adam Ceroi^{1,2}

¹EFS Bourgogne Franche-Comté, Université Bourgogne Franche-Comté, Inserm, UMR1098, Besançon, F-25000, France

²The Center for Cell Clearance, University of Virginia, Charlottesville, VA, 22903, USA

V2 First published: 10 Apr 2017, 6:456
<https://doi.org/10.12688/f1000research.11332.1>

Latest published: 22 Jun 2017, 6:456
<https://doi.org/10.12688/f1000research.11332.2>

Abstract

There are more and more data concerning the role of cellular metabolism in innate immune cells, such as macrophages or conventional dendritic cells. However, few data are available currently concerning plasmacytoid dendritic cells (PDC), another type of innate immune cells. These cells are the main type I interferon (IFN) producing cells, but they also secrete other pro-inflammatory cytokines (e.g., tumor necrosis factor or interleukin [IL]-6) or immunomodulatory factors (e.g., IL-10 or transforming growth factor- β). Through these functions, PDC participate in antimicrobial responses or maintenance of immune tolerance, and have been implicated in the pathophysiology of several autoimmune diseases, as well as in tumor immune escape mechanisms. Recent data support the idea that the glycolytic pathway (or glycolysis), as well as lipid metabolism (including both cholesterol and fatty acid metabolism) may impact some innate immune functions of PDC or may be involved in these functions after Toll-like receptor (TLR) 7/9 triggering. The kinetics of glycolysis after TLR7/9 triggering may differ between human and murine PDC. In mouse PDC, metabolism changes promoted by TLR7/9 activation may depend on an autocrine/paracrine loop, implicating type I IFN and its receptor IFNAR. This could explain a delayed glycolysis in mouse PDC. Moreover, PDC functions can be modulated by the metabolism of cholesterol and fatty acids. This may occur via the production of lipid ligands that activate nuclear receptors (e.g., liver X receptor [LXR]) in PDC or through limiting intracellular cholesterol pool size (by statin or LXR agonist treatment) in these cells. Finally, lipid-activated nuclear receptors (i.e., LXR or peroxisome proliferator activated receptor) may also directly interact with pro-inflammatory transcription factors, such as NF- κ B. Here, we discuss how glycolysis and lipid metabolism may modulate PDC functions and how this may be harnessed in pathological situations where PDC play a detrimental role.

Open Peer Review

Approval Status

	1	2	3
version 2			
(revision)			
22 Jun 2017		view	
version 1			
10 Apr 2017	view	view	view

- Vassili Soumelis**, PSL Research University, Paris, France
Francois Xavier Danlos, Institut Curie, Paris, France
- Nathalie Bendriss-Vermare**, Cancer Research Centre of Lyon (CRCL), Lyon, France
- Edward J. Pearce**, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany
Katarzyna Grzes, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Any reports and responses or comments on the article can be found at the end of the article.

Keywords

plasmacytoid dendritic cells, immunometabolism, cholesterol, fatty acid, LXR, PPAR, type I interferon, glycolysis

Corresponding author: Philippe Saas (philippe.saas@efs.sante.fr)

Author roles: **Saas P:** Conceptualization, Funding Acquisition, Supervision, Validation, Writing – Original Draft Preparation, Writing – Review & Editing; **Varin A:** Conceptualization, Writing – Review & Editing; **Perruche S:** Conceptualization, Writing – Review & Editing; **Ceroi A:** Conceptualization, Validation, Writing – Review & Editing

Competing interests: The authors declare that they have no competing interests.

Grant information: The work in this field is supported by the Agence Nationale de la Recherche (LabEx LipSTIC; ANR-11-LABX-0021), and the Conseil Régional de Bourgogne Franche-Comté ("soutien au LabEx LipSTIC" 2016).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2017 Saas P *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Data associated with the article are available under the terms of the [Creative Commons Zero "No rights reserved" data waiver](#) (CC0 1.0 Public domain dedication).

How to cite this article: Saas P, Varin A, Perruche S and Ceroi A. **Recent insights into the implications of metabolism in plasmacytoid dendritic cell innate functions: Potential ways to control these functions [version 2; peer review: 3 approved]** F1000Research 2017, 6:456 <https://doi.org/10.12688/f1000research.11332.2>

First published: 10 Apr 2017, 6:456 <https://doi.org/10.12688/f1000research.11332.1>

REVISED Amendments from Version 1

The major changes in the revised version concern the role of plasmacytoid dendritic cells (PDC) in tumors. It has been shown by several teams that PDC infiltrate different solid tumors and this may be associated with a poor prognosis. We have added to the revised version references to different manuscripts (original works describing these features). Several mechanisms may explain that PDC present in a given tumor favor tumor progression. Among these mechanisms, one concerns their innate immune functions discussed in this review: defective type I interferon production. Metabolism may play an important role in both tumor progression and antitumor immunity. This may also affect tumor-infiltrating PDC functions. Changes have been made mainly in sections 2.3 and 2.4.

We have also modified [Figure 2](#) and added a Table summarizing the impact of pharmacological agents targeting the different metabolic pathways on TLR7/9 stimulation.

Minor corrections have been made throughout the text according to reviewer's comments.

See referee reports

1. Introduction

More and more data are available concerning the role of cellular metabolism in innate immune cells, such as macrophages or conventional dendritic cells (cDC)¹⁻³. However, few data are available currently concerning plasmacytoid dendritic cells (PDC). PDC belong to the family of dendritic cells (DC) and possess specific features that distinguish them from cDC. PDC represent the main type I interferon (IFN) secreting cells and play a critical role in antimicrobial immune responses. The involvement of PDC through IFN- α secretion has also been reported in several autoimmune diseases (see section 2.4). Furthermore, PDC release other pro-inflammatory cytokines, as well as immunoregulatory factors. In these ways, they may exert pro-inflammatory functions or, on the contrary, participate in tolerance mechanisms. In this Review article, based on recent publications⁴⁻⁶, we will discuss how the innate immune functions of PDC may be modulated by or dependent on the glycolytic pathway (also known as glycolysis) and lipid metabolism, including the metabolism of cholesterol and fatty acids. Before that, we will describe the innate functions of PDC. PDC also have the capacity to present antigens to T cells and to polarize CD4⁺ helper T cell responses, as well as those interacting with B cells⁷. These functions will not be discussed in this article, since no sufficient data are available concerning the impact of metabolism on the capacity of PDC to interact with the adaptive immune system. Although the "immunometabolism" (as defined in Ref# 2) includes six metabolic pathways (glycolysis, the tricarboxylic acid [TCA] cycle, the pentose phosphate pathway, fatty acid oxidation, fatty acid synthesis and amino acid metabolism) that influence immune cell effector functions², this article will focus on glycolysis and lipid metabolism (extended to the cholesterol metabolism). Concerning amino acid metabolism, PDC innate functions have been shown to be modulated by mammalian target of rapamycin (mTOR) signaling. This central metabolic regulator, mTOR can sense amino acid sufficiency in lysosomes, and promotes mRNA translation and lipid synthesis to support cell growth and proliferation². Furthermore,

mTOR, through its association with regulatory-associated protein of mTOR (RAPTOR), constitutes the mTOR complex 1 (mTORC1), which is connected with other metabolic pathways (see a recent review⁸ and section 3.1). This will be discussed briefly, since the role of mTOR in innate immune cell functions has been reviewed recently^{3,8,9}. Finally, concerning amino acid metabolism, PDC are able to sense amino acid deficiency through their expression of GCN2 (general control nonderepressible 2) serine/threonine kinase. Indeed, the suppression of interleukin (IL)-6 production in PDC by indoleamine 2,3-dioxygenase (IDO) involves GCN2 kinase¹⁰ (see section 2.3).

What are the main roles of the immunometabolism in immune cells? First of all, this is a way to provide energy. Cells need energy to execute cellular functions, such as survival, proliferation or cytokine secretion. This energy is provided as adenosine triphosphate (ATP) by several pathways. The first is glycolysis, which involves the conversion of glucose to pyruvate in the cytosol. The second pathway is the TCA cycle (also called the Krebs cycle), which donates electrons to the electron transport chain located in the mitochondria to fuel oxidative phosphorylation or respiration (OXPHOS). This OXPHOS process generates ATP in the mitochondria. Other substrates, such as fatty acids *via* β -oxidation (also called fatty acid oxidation [FAO]), can replenish the TCA cycle to fuel OXPHOS¹¹. In addition to substrates used for energy production and *de novo* biosynthesis, mitochondrial metabolic pathways (such as the TCA, FAO, or OXPHOS) provide substrates for epigenetic modifications of DNA and histones^{12,13}. This is the case, for instance, of acetyl-CoA for histone acetylation, which is associated with active transcription¹². This connects mitochondrial metabolism to epigenetic regulation¹³. This specific aspect will be briefly discussed in the Conclusions of this article.

2. The innate immune functions of plasmacytoid dendritic cells

PDC belong to the DC family and possess specific features that distinguish them from cDC¹⁴. These features include: the capacity to rapidly and massively produce type I IFN (*i.e.*, IFN- α/β), the expression of a particular set of pattern-recognition receptors (PRR), leading to the recognition of specific pathogen-associated molecular pattern (PAMP) and damage-associated molecular pattern (DAMP) molecules, as well as a preferential localization in lymphoid organs⁷.

PDC were firstly identified in human as the major IFN- α producing cells, and thus initially called IPC (IFN- α producing cells)^{15,16}. After this characterization in human, its murine PDC counterpart was then isolated¹⁷⁻²⁰. Human PDC are usually identified as CD4⁺, CD303⁺ (previously known as BDCA-2), CD123^{high}, and CD11c⁻, whereas mouse PDC are CD11c^{int}, B220⁺, SIGLEC-H⁺, and CD317⁺ (also known as BST2 or PDCA1)⁷. Despite the difference in phenotypes of human and mouse PDC, PDC from both species exhibit a conserved genetic signature with some common genes (*e.g.*, *tlr7* or *ifr7*)²¹. Moreover, PDC exhibit specific transcription factors, such as the transcription factor E2-2 (also known as TCF4) or SPIB⁷. A differentiation/ontogeny process distinct from those of cDC has been reported⁷.

2.1. PDC ontogeny and localization

Development of PDC from hematopoietic stem cells occurs in the bone marrow. After this differentiation step, PDC are released from the bone marrow to the blood for homing to different lymphoid tissues²². Thus, PDC isolated from blood of healthy donors or patients consist in PDC migrating to these tissues⁷. In steady state, PDC reside mainly in T cell-rich areas in lymph nodes and secondary lymphoid organs⁷. Localizations of PDC in other lymphoid organs, such as Peyer's patches of the gut^{23,24}, and tonsils²⁵, have been reported. PDC residing in non-lymphoid tissue – such as the airways²⁶ and the liver²⁷ – exert a critical role in steady state by regulating mucosal immunity and maintaining tolerance to inhaled or ingested antigens²⁸. Finally, PDC are also present in the thymus during homeostatic conditions, where they play a role in central tolerance^{29–31}. In contrast, during infections or autoimmune diseases, PDC migrate to inflamed lymph nodes¹⁵ or inflamed epithelia^{15,25,32}. Moreover, PDC infiltrate several tumors including: melanoma³³, head and neck³⁴, breast^{35–37} and ovarian^{38–40} tumors. The microenvironment in which PDC are present may influence oxygen and nutrient availability, which impacts on metabolic pathways (see section 3).

2.2. Type I IFN and pro-inflammatory cytokines secreted by PDC

PDC constitute a DC subset, specialized in antimicrobial immune responses. This occurs mainly through a rapid type I IFN (IFN- α/β) production^{7,41,42}. Selective depletion of PDC by genetic approaches supports the critical role of PDC for early IFN- α production after microbial infections^{43–45}. The type I IFN response is triggered by Toll-like receptor (TLR) signaling after PAMP recognition.

Compared to cDC, PDC express a limited number of PRR. TLR 7/9 are expressed by both human and mouse PDC^{7,46}. These two endoplasmic TLRs allow PDC to recognize cytosine-phosphate guanosine (CpG)-rich unmethylated DNA from bacteria and DNA viruses,^{7,41,47} as well as viral single-stranded RNA (ssRNA),^{41,48,49} respectively. In addition, PDC are able to recognize *via* TLR7/9 mammalian nucleic acids⁵⁰, in particular when these nucleic acids are complexed or associated with antimicrobial peptides (e.g., LL37)^{51,52}. Once PDC have sensed pathogens or DAMP through endoplasmic TLR, signaling is mediated *via* MyD88 (myeloid differentiation factor 88), a docking protein for IRAK1/4 (IL-1R-associated kinase 1/4), and the ubiquitin ligase TRAF6 (tumor necrosis factor [TNF] receptor-associated factor 6). IFN-regulatory factor 7 (IRF7) is then phosphorylated and translocates into the nucleus to induce *type I IFN* gene and IFN-inducible gene transcription (Figure 1)⁵³. This is true for human PDC⁴⁶. Concerning mouse PDC, other intermediates may participate in *type I IFN* mRNA transcription in the TLR-dependent IRF7 signaling pathway. This involves a complex, associating TRAF3, IRAK1, osteopontin, PI3K (phosphatidylinositol 3-kinase) and IKK α (I κ B kinase- α)⁴⁶. A critical role of PI3K has also been reported for type I IFN production by human PDC⁵⁴. In addition, in TLR7- or TLR9-activated human PDC, TRAF6 can also recruit TAK1 (transforming growth factor [TGF]- β -activating kinase; also known as MAP3K7 for mitogen-activated protein kinase kinase kinase 7) to trigger the synthesis of pro-inflammatory cytokines *via* NF- κ B activation⁴⁶. In mouse PDC, TAK-1/MAP3K7 activates the mitogen-activated protein kinase (MAPK) pathway that upregulates costimulatory molecule expression (e.g., CD40, CD80 or CD86)⁴⁶. Both human and mouse PDC have been shown to secrete TNF- α ^{4–6,55,56}, IL-6^{4–6,55,56}, IL-8^{55–57} or granulocyte macrophage

Figure 1. The main signaling pathways in plasmacytoid dendritic cells that promote metabolic changes or are modulated by metabolic pathways. This figure summarizes different signaling pathways described in the literature to promote metabolic changes or to be modulated by immunometabolism in plasmacytoid dendritic cells. This includes: endosomal TLR 7 and TLR9, membrane IL-3 receptor (associating CD131 to CD123), GM-CSF receptor (associating CD131 to CD116), and IFN- α receptor (IFNAR associating IFNAR1 and IFNAR2). Only the main pathways with main effector molecules are depicted. For more details, please refer to the main text. Abbreviations (not defined in the main text): *IFIG*, IFN-I-induced genes; *nfkB1*, NF- κ B gene.

colony-stimulating factor (GM-CSF)⁵⁵. This TLR-induced cytokine synthesis is regulated in PDC by the translocation of NF- κ B, p38 MAPK and c-Jun N-terminal kinase (JNK) into the nucleus. In human PDC, the association of NF- κ B p65 and p50 subunits with IRF5 appears to be the master inducer of *IL-6* mRNA transcription⁴⁶. Depending on the TLR9 ligand used, the cytokine response can be different. For instance, type A CpG-containing oligonucleotide (CpG-ODN) (CpGA) induces mainly type I IFN production, whereas type B CpG-ODN (CpGB) induces pro-inflammatory cytokine secretion and upregulation of co-stimulatory molecules⁵⁸.

In addition to virus or pathogen-expressing TLR7/TLR9 ligands or synthetic ligands, PDC can be activated to release cytokines by other stimuli, including DAMP. PDC express RAGE (receptor for advanced glycation end products), a PRR that recognizes high-mobility group box-1 (HMGB1)^{59,60}, a nuclear DNA-binding protein released from necrotic cells⁶¹. PDC can also be activated by neutrophil extracellular traps (NET), released by dying or activated neutrophils. These NET contain DNA fibers, histones, as well as a large amount of LL37 and HMGB1^{62,63}. Human PDC can also be activated by CD154 from activated platelets⁶⁴ or endothelial-derived microvesicles^{6,56}. Other PRR are present in the cytoplasm of PDC and dedicated to RNA virus recognition. This is the case of retinoic acid-inducible gene (RIG)-I-like receptors, DHX9 or DHX36⁶⁵.

2.3. Regulatory or immunosuppressive factors expressed by PDC

In addition to type I IFN and pro-inflammatory cytokine production, PDC have regulatory and immunosuppressive functions²⁸. This has been demonstrated by *in vivo* PDC depletion studies^{26,66}. For instance, PDC exert immunoregulatory functions in the lung, preventing deleterious asthmatic reactions²⁶. PDC have been shown to prevent allo-immune responses in the setting of solid organ transplantation⁶⁷ or after hematopoietic cell transplantation⁶⁸. PDC participate also in oral tolerance⁶⁹. Moreover, PDC may express immunosuppressive factors that confer tolerogenic properties²⁸. One major factor is the enzyme IDO^{28,70,71}. This enzyme is involved in the catabolism of the essential amino acid, tryptophan, and the synthesis of kynurenines. Tryptophan is required for T cell proliferation and kynurenines have immunosuppressive properties. Engagement of several receptors, including CD80/CD86, or TLR9⁷², participates in active IDO induction. Amino acid withdrawal resulting from IDO enzymatic activity, stimulates the GCN2 kinase in PDC and then prevents IL-6 secretion by PDC¹⁰. Moreover, IDO exerts a regulatory function independently of its catabolic activity by participating in TGF- β -signaling pathway⁷³. Receptors expressed by PDC, such as immunoglobulin-like transcript 7⁷⁴ or CD303⁷⁵ may also inhibit TLR7/9-mediated type I IFN production. In addition, PDC can produce, under certain circumstances, high levels of immunosuppressive cytokines, such as IL-10^{20,27} or TGF- β ^{66,76}. In addition, PDC participate in the maintenance of immune tolerance *via* the induction and/or expansion of regulatory T cells (please refer to Refs^{7,76}; this is out of the scope of this review).

When one evokes cellular metabolism, cell survival has to be discussed. IL-3 has been identified as a critical factor for the development and survival of PDC^{77,78}. This cytokine interacts with the IL-3 receptor associating two chains, the common chain CD131 and the IL-3R α chain (CD123) that is highly expressed by PDC. Signaling through this receptor involves Janus kinase 2 (JAK2), Src kinases, transcription factors STAT3/STAT5 (signal transducer and activator of transcription 3/5) and Akt (Figure 1)⁷⁹. Another cytokine that shares the common chain CD131 and influences PDC survival with nearly the same signaling pathway is GM-CSF (Figure 1)⁷⁸. Finally, PDC express IFNAR, the membrane receptor for type I IFN (IFN- α or IFN- β) that consists of two subunits, IFNAR1 and IFNAR2. Engagement of this receptor by its ligand activates JAK1 (associated with IFNAR1) and tyrosine kinase 2 (associated with IFNAR2) that phosphorylate and activate STAT1 and STAT2, respectively (Figure 1)^{79,80}.

2.4. Implications of PDC in diseases

Before discussing the role of immunometabolism, the role of PDC in beneficial and detrimental immune responses will be briefly detailed. As type I IFN producing cells, PDC play a major beneficial role in antimicrobial immune responses⁷. However, uncontrolled IFN- α production in acute viral infection may be detrimental to the host. Moreover, high levels of type I IFN released by PDC may be detrimental in chronic inflammatory or autoimmune diseases^{7,64,81–84}. This is the case of systemic lupus erythematosus (SLE)^{62–64}, type 1 diabetes⁸², and psoriasis^{51,84}. Furthermore, PDC may participate in inflammatory autoimmune disorders (*i.e.*, systemic sclerosis⁸³ or autoimmune vasculitis⁸⁵) *via* the secretion of other pro-inflammatory cytokines than type I IFN⁸⁵ or chemokines⁸³. Since PDC infiltrate inflamed tissues, they may release pro-inflammatory factors participating in the amplification of diseases. Therefore, PDC have been reported to infiltrate acute graft-versus-host disease lesions, including gastro-intestinal⁸⁶ and cutaneous⁸⁷ lesions. PDC emerge as cells present in atherosclerotic plaques and may play a role in atherosclerosis^{79,88}. Atherosclerotic plaques are enriched in lipids. This may modify the lipid metabolism of infiltrated PDC by the uptake of lipid-enriched lipoproteins or oxidized lipoproteins, and subsequently PDC functions (see section 3.3.3). Finally, insufficient or exhausted production of IFN- α during chronic viral infections (e.g., chronic hepatitis C virus or HIV) has also been reported^{89,90}. Furthermore, as stated before, PDC have been shown to infiltrate tumors^{33–40} and the presence of infiltrating PDC have been associated with a poor prognosis in some tumors^{35,36,39,40}. Defective type I IFN production by tumor-infiltrating PDC has been identified as one potential mechanism explaining tumor progression^{34,35,38,91,92}. Thus, the metabolism of PDC may be pharmacologically modified in order to restore type I IFN production. The pathological microenvironment in which PDC are present may impact on PDC metabolism and subsequently on their functions. This is particularly true for tumor-infiltrating PDC, since metabolic dysregulation is a common and well-recognized feature of cancer^{93–95}. Today, this has been mainly studied in infiltrating T cells and macrophages.

3. The influence of the metabolism on innate immune functions of plasmacytoid dendritic cells

3.1. PDC innate immune functions and mTOR signaling

The kinase mTOR is a key regulator of different biological processes, including metabolism^{8,9}. This is a serine/threonine protein kinase that senses and integrates signals (such as nutrients and oxygen) originating from the extracellular milieu, as well as intracellular signals⁹⁶. In fact, mTOR is the catalytic subunit of two different complexes, mTORC1 and mTORC2. As mentioned briefly in the Introduction, mTORC1 is connected with several metabolic pathways. Indeed, mTORC1 promotes glycolysis through hypoxia-inducible factor 1 α (HIF-1 α)⁹, as well as cholesterol and fatty acid synthesis using TCA cycle intermediates through a pathway involving sterol regulatory element-binding proteins (SREBP) and the nuclear receptor, peroxisome proliferator-activated receptor (PPAR) γ ⁹. Cholesterol and fatty acids are used as “building blocks”⁹ for complete maturation of endoplasmic reticulum (ER) and Golgi apparatus. Both organelles can promote the transport of pro-inflammatory cytokines within the cell that precedes their secretion⁹. In addition, mTORC1 can have a negative effect on mitochondrial OXPHOS by inducing the expression of type I IFN and production of nitric oxide, which subsequently promotes aerobic glycolysis⁹. This has been well described in macrophages⁹.

Concerning PDC innate immune functions, mTOR plays an important role in type I IFN production⁹⁷. The TLR9 ligand, CpGA, stimulates the rapid phosphorylation of mTOR and its downstream targets, the p70 ribosomal S6 kinase 1 and the eukaryotic translation initiation factor 4E-binding protein (4E-BP)⁹⁷. Thus, mTOR is involved in the TLR9-induced type I IFN signaling pathway (Figure 2). Using the mTORC1 inhibitor rapamycin, the same authors demonstrated that TLR7/9-mediated production of type I IFN is inhibited in both human and mouse PDC⁹⁷. These data have been confirmed *in vivo* using live attenuated viral yellow fever vaccine⁹⁷. The virus responsible for yellow fever is an ssRNA virus and TLR7 recognizes ssRNA⁴⁸. Rapamycin may act at two levels: *i*) by inactivating *via* the inhibition of 4E-BP phosphorylation the nuclear translocation of IRF7 required for type I IFN gene transcription; and *ii*) by blocking the formation of the TLR9-MyD88 complex *via* the p70 ribosomal S6 kinase 1⁹⁷. In addition to type I IFN production, the inhibition of mTORC1 reduces TLR7/9-induced TNF and IL-6 production by human and mouse PDC⁹⁷. Overall, mTOR signaling is involved in the TLR9-induced type I IFN signaling pathway and blocking mTORC1 inhibits TLR7/9-stimulated secretion of pro-inflammatory cytokines (*i.e.*, type I IFN, TNF and IL-6) by PDC. Thus, the use of mTOR inhibitors may block the detrimental pro-inflammatory functions of PDC in inflammatory disorders, but may also prevent the beneficial antimicrobial response of PDC.

Lastly, mTORC1 stimulates glycolysis in innate immune cells, at least *via* HIF-1 α induction, but also through the increased expression of the glucose transporter 1 (GLUT1) at the cell surface (Figure 2)⁹. GLUT1 enhances glucose uptake from the extracellular milieu⁹. Thus, the implication of mTOR signaling pathway in the response of PDC to TLR9 ligand⁹⁷ suggests that glycolysis may be triggered in the cells. This will be discussed in the next section.

3.2. PDC innate immune functions and glycolysis

The glycolytic pathway (also known as glycolysis) involves the uptake of extracellular glucose (*i.e.*, present in the microenvironment) and its conversion in the cytosol to generate pyruvate². Most pyruvate is then excreted from the cells as lactate after a process called aerobic glycolysis. This is a relatively inefficient pathway for the generation of energy (*i.e.*, cellular ATP) compared to the TCA cycle coupled to OXPHOS⁹⁸. The preferential use of glycolysis *versus* the TCA cycle and OXPHOS depends on oxygen availability^{2,98}. Glycolysis is favored during hypoxia, a situation encountered, for instance, in joints during rheumatoid arthritis or in the inflamed colon during Crohn's disease⁹⁸ - PDC can be present in both inflamed tissues (*i.e.*, the synovial fluid⁹⁹⁻¹⁰¹ and the colon^{86,102}). Regions of hypoxia are also present in solid tumors⁹⁵ infiltrated by PDC. This energy provided by glycolysis may represent the resources necessary for cytokine secretion, since PDC does not proliferate in the same way as adaptive cells (*i.e.*, T cells). However, PDC become highly secretory upon activation⁷. Finally, growth factors triggering PI3K and MAPK in their signaling pathway promote, in theory, the cellular use of glycolysis². This may be the case when PDC are stimulated by TLR7/9 ligands (see previous section).

The exposure of human PDC to two different ssRNA viruses, influenza virus (Flu) and Rhinovirus (RV) – triggering the TLR7 pathway *via* ssRNA recognition⁴⁸ – activates HIF-1 α ⁴, a major regulator of metabolism (Figure 2A). Indeed, HIF-1 α is critical for glycolysis to generate ATP, since it induces the expression of different glycolytic enzymes, such as hexokinase and phosphofructokinase⁹⁸. In addition to HIF-1 α activation, the TLR7 agonist gardiquimod, as well as Flu and RV, induces early glycolysis (within minutes) in human PDC, as attested by elevated extracellular acidification rate (ECAR; a reflection of lactate secretion in extracellular milieu, an indicator of glycolysis in real time) and elevated rates of lactate production⁴. Moreover, the inhibition of glycolysis by 2-deoxyglucose (2-DG; a glycolytic inhibitor) impairs ssRNA virus- or TLR7 ligand-induced type I IFN by PDC, as well as the upregulation of HLA-DR, CD80 and CD86 at PDC cell surface⁴. Furthermore, 2-DG inhibits the increase of *IFNA*, *CD80* and *CD86* mRNA induced by exposure to Flu⁴. This suggests that glycolysis induced by the TLR7 pathway regulates these genes at the transcriptional level. The involvement of the TLR7 pathway in glycolysis was supported by the use of chloroquine, known to disrupt endosomal acidification required for TLR7 signaling¹⁰³. Chloroquine treatment inhibits the lactate production by PDC in response to Flu or gardiquimod⁴. Overall, ssRNA viruses enhance glycolysis in human PDC *via* the TLR7 pathway (Figure 2A). This finding was confirmed *in vivo*, since viral infection using live attenuated influenza vaccine increases glycolysis in *ex vivo* isolated human PDC and correlates with IFN- α production by these cells⁴.

These data contrast with a recent report showing that mouse PDC activation in response to the TLR9 ligand, CpGA, is not accompanied by a rapid change in ECAR (*i.e.*, during the first 150 minutes). This contrasts with data obtained in the same experiments using cDC – as a control of PDC – stimulated by either lipopolysaccharide, Poly(I:C) or CpGA⁵. However, glycolysis is detected late (24 hours) in TLR9-stimulated mouse PDC⁵.

Moreover, the authors also studied the role of the TLR7 pathway in mouse PDC, but not extensively. Again, they found a delayed activation of glycolysis after stimulation of mouse PDC with the TLR7 agonist imiquimod⁵. Thus, whether the origin of PDC (human⁴ *versus* mouse⁵) or their source (sorted from peripheral blood mononuclear cells⁴ *versus* sorted from FLT3 ligand-stimulated bone marrow cultures⁵) may explain this discrepancy remains to be determined. Another difference between these two studies lies in the direct effect of IFN- α on PDC metabolism. Treatment of human PDC with IFN- α is not sufficient to induce PDC lactate efflux (*i.e.*, glycolysis) and IFN- α/β receptor (IFNAR) blockade does not affect PDC lactate efflux induced by Flu infection⁴. This suggests that type I IFN does not regulate in an autocrine/paracrine manner Flu-induced early glycolysis in human PDC. In contrast, this autocrine/paracrine loop involving type I IFN and its receptor may play a significant role in TLR-induced glycolysis in mouse PDC (Figure 2B)⁵. Nevertheless, all these data support that glycolysis plays a role as a source of energy in the production of type I IFN, pro-inflammatory cytokines (IL-6 and TNF) and costimulatory molecule upregulation by PDC in response to TLR7/9 activation. The modulation of this metabolic pathway may limit uncontrolled pro-inflammatory cytokines by PDC in pathological situations or may restore type I IFN production in chronic infectious diseases or in solid tumors.

3.3. PDC innate immune functions and lipid metabolism

In this section, we will discuss fatty acid metabolism, including fatty acid oxidation (FAO; also known as mitochondrial β -oxidation) and fatty acid synthesis, as well as cholesterol metabolism. Lipid metabolism is regulated by many key enzymes. Some of these enzymes involved in *de novo* lipid synthesis are controlled by lipid-activated nuclear receptors, such as liver X receptor (LXR) or PPAR. The genes coding for these enzymes are thus called LXR or PPAR target genes, respectively. Among these LXR or PPAR target genes, one may cite *FASN* coding for fatty acid synthase^{104–106}. These LXR or PPAR target genes code not only for enzymes involved in lipid metabolism, but also for transcription factors and transporters, and regulate also glucose or amino acid metabolism. This is the case of the transcription factors, SREBP, or of glucose or cholesterol transporters involved in nutrient entry (*e.g.*, the GLUT1 glucose transporter) or efflux, such as ATP binding cassette (ABC) transporters A1 and G1 (ABCA1 and ABCG1, respectively) involved in cholesterol efflux^{2,104,105,107,108}. PPAR and LXR are both mainly found associated with retinoid X receptor (RXR) to form a heterodimer. Considered as permissive heterodimer receptors, they can be activated by the ligands of each partner (*e.g.*, PPAR or RXR ligands; LXR or RXR ligands)^{106,108}. While the involvement of these nuclear receptors in innate immune responses is well described for macrophages and cDC¹⁰⁸, few data are available for PDC. Here, we will discuss how lipid metabolism modulates PDC innate immune functions and how PDC activation by TLR ligands or other stimuli modifies lipid metabolism.

3.3.1. Fatty acid oxidation. The FAO pathway allows the conversion of fatty acids into numerous products in the mitochondria. These products, such as acetyl-CoA, NADH (nicotinamide adenine

dinucleotide dehydrogenase) and FADH₂ (the fully reduced form of flavin adenine dinucleotide [FAD]), can be used in the TCA cycle and the electron transport chain to generate energy². As discussed before, normoxia supports the TCA cycle and OXPHOS, while hypoxia *via* HIF-1 α activation followed by the induction of glycolytic enzymes leads to glycolysis^{2,98}. The TCA cycle coupled to OXPHOS is the major metabolic pathway used by most quiescent or non-proliferating cells².

A recent well-received manuscript reports that FAO and mitochondrial OXPHOS play a critical role in murine PDC activation by the TLR9 pathway (Figure 2B)⁵. This is particularly well demonstrated for type I IFN production by these cells⁵. Mouse PDC stimulated by the TLR9 ligand, CpGA, exhibit an increase of basal oxygen consumption rate (OCR) and spare respiratory capacity (SRC)⁵. Both increased basal OCR and SRC are indicators of FAO. To directly demonstrate that CpGA increases FAO, the authors used etomoxir, an irreversible inhibitor of carnitine palmitoyl transferase 1. This enzyme is responsible for the entry of activated fatty acids (*i.e.*, medium-chain and long-chain fatty acids conjugated with carnitine) into mitochondria for FAO². Etomoxir inhibits both the increase of basal OCR and SRC induced by TLR9 ligand stimulation. Moreover, etomoxir limits the production of IFN- α and pro-inflammatory cytokines (TNF- α and IL-6) by PDC in response to CpGA stimulation. This inhibition of TLR9 activation by etomoxir also prevents the upregulation of CD86 expression at PDC cell surface⁵. Overall, TLR9-induced mouse PDC activation is accompanied by an increased FAO, and stimulation of this metabolic pathway is required for pro-inflammatory cytokine secretion and PDC maturation (*i.e.*, CD86 upregulation).

An increase of basal OCR and SRC attesting for FAO has also been observed after the activation of mouse PDC by the TLR7 agonist imiquimod. Treatment of mouse PDC by etomoxir inhibits imiquimod-induced IFN- α production⁵, suggesting that FAO is also required for type I IFN production in response to TLR7 ligand. Implication of FAO *in vivo* was assessed using etomoxir and mice infected with the ssRNA lymphocytic choriomeningitis virus (LCMV). Etomoxir-treated and LCMV-infected mice exhibit reduced circulating IFN- α 3 days after infection and significantly more LCMV are detected in the liver and spleen of etomoxir-treated *versus* untreated infected mice⁵. This demonstrates the *in vivo* relevance of these data.

Changes in basal OCR are not detected at early time points after murine PDC activation by CpGA, but this requires new gene transcription. This may suggest that IFN- α production and IFNAR signaling induced by CpGA stimulation may be responsible for these changes in PDC metabolism. Indeed, treatment with IFN- α alone is sufficient to induce increased FAO in mouse PDC⁵. Thus, increased FAO induced by CpGA stimulation in mouse PDC are therefore the results of an autocrine or paracrine loop involving the type I IFN signaling pathway.

One goal of the FAO pathway is to generate energy, by the production of a high number of ATP molecules². This occurs in fact by fueling OXPHOS². To definitively demonstrate the implication of energy provided by FAO coupled to OXPHOS in type I

IFN-induced mouse PDC activation, ATP was quantified in response to IFN- α and different inhibitors were used⁵. Metabolic reprogramming of mouse PDC induced by IFN- α leads to enhanced ATP availability⁵. The quantity of ATP in response to CpGA activation is significantly reduced by the inhibition of either FAO (using etomoxir), pyruvate import into mitochondria required for the TCA cycle (using UK5099) or fatty acid synthesis (using tall oil fatty acid [TOFA])⁵. This confirms that type I IFN stimulation of mouse PDC generates significant amounts of ATP *via* the FAO pathway. This pathway fuels OXPHOS in this setting and is itself fueled by fatty acid synthesis, as demonstrated by the use of the inhibitor TOFA (Figure 2B).

The pathways responsible for the changes in metabolism induced by type I IFN in mouse PDC were studied by an unbiased RNA-seq based approach⁵. This analysis shows that OXPHOS is the major network induced by type I IFN, and FAO is connected to this network. Furthermore and surprisingly, this analysis reveals also a PPAR α gene signature⁵. While PPAR γ is expressed in macrophages and cDC¹⁰⁸, the PPAR α isoform is mainly and highly expressed in metabolic active tissues, such as the liver or brown adipose tissues¹⁰⁶. After having confirmed that the PPAR α isoform is expressed by bone marrow-derived and splenic mouse PDC, a PPAR α antagonist, GW6471 was used⁵. GW6471 blocks both IFN- α production and the increase of basal OCR in response to CpGA activation. Furthermore, increased basal OCR and SRC in mouse PDC are observed after incubation with a PPAR α agonist gemfibrozil, as well as with the combined PPAR α and PPAR γ agonist, muraglitazar⁵. Overall, this indicates that PPAR α is involved in FAO and OXPHOS induced by CpGA activation (Figure 2B). This PPAR α pathway in PDC functions will be discussed later in this review together with the other lipid-activated nuclear receptor, LXR (see the following two sections).

3.3.2. Fatty acid synthesis. The fatty acid synthesis pathway allows cells to generate lipids that are necessary for cellular growth and proliferation². Fatty acid synthesis is performed in the cytosol, and it uses citrate from the TCA cycle and exported from the mitochondria into the cytosol to generate fatty acids (Figure 2B). As mentioned above, *de novo* fatty acid synthesis is dependent on key enzymes, such as FASN, that are controlled by either the mTOR signaling pathway⁹, LXR^{104,105} or SREBP-1c^{2,109}. Fatty acids generated by this synthesis can be used to fuel mitochondrial FAO², to activate PPAR nuclear receptors¹⁰⁷, or can be condensed with glycolysis-derived glycerol to produce triacylglycerol and phospholipids². These latter two are key components of many cellular structures, such as the cell membrane, ER or Golgi apparatus^{2,9}.

The inhibition of the fatty acid synthesis using two different inhibitors (TOFA, an inhibitor of acetyl-CoA carboxylase; C75, an inhibitor of FASN)² prevents the increase of IFN- α , TNF- α , and IL-6 production by mouse PDC in response to CpGA stimulation⁵. As previously demonstrated for FAO and OXPHOS, fatty acid synthesis induced by the TLR9 pathway implicates a type I IFN/IFNAR loop⁵. Moreover, using the TOFA inhibitor before measuring both the quantity of ATP in response to CpGA activation and the expression of PPAR α target genes, *Acadl* and *Pltp* in CpGA-activated

mouse PDC⁵ allowed the authors to conclude that fatty acid synthesis induced in mouse PDC rather fuels FAO and OXPHOS than provides lipid ligands for PPAR α activation. It is well described that the natural ligands of PPAR α include different fatty acids, as well as numerous fatty acid derivatives and compounds with structural resemblance to fatty acids, such as acyl-CoAs, or oxidized fatty acids¹⁰⁷. Here in PDC, fatty acids synthesized in response to the TLR9 signaling pathway do not seem to directly stimulate PPAR α by providing PPAR α ligands. One may hypothesize that, as reported for lipid-activated nuclear receptors^{104,106}, activation of PPAR α by TLR9 ligand may interfere with transcription factors^{3,106} that are critical for pro-inflammatory cytokine secretion by PDC (see section below).

3.3.3. Cholesterol metabolism. Cholesterol is one of the major constituents of lipid rafts together with glycosphingolipids¹¹⁰. Cellular cholesterol content results from cholesterol uptake and biosynthesis through the mevalonate pathway, while its elimination from cells is mediated by cholesterol efflux. Cholesterol uptake involves plasma lipoproteins (mainly low density lipoprotein [LDL] and very low density lipoprotein [VLDL]) after interactions with their specific receptors, LDLR and VLDLR, respectively. Cholesterol efflux is mainly mediated by specific transporters, ABCA1 and ABCG1, in association with extracellular cholesterol acceptors, including apolipoproteins (APO) APOA1 and APOE, or lipoprotein particles (e.g., nascent high density lipoprotein [HDL] or HDL2) (Figure 3)¹¹¹. ABCG1 is rather localized within the cell and seems to move sterols between intracellular compartments¹⁰⁶. ABCA1 is more dedicated to extrude cholesterol derivatives outside the cell¹⁰⁶. Cholesterol regulates critical cellular functions, including plasma membrane formation and fluidity, allowing the clustering of receptors into lipid rafts for efficient signaling¹¹⁰. These latter functions are implicated in signaling pathway regulation. Localization of signaling complexes within the lipid rafts is critical for certain receptors.

Cholesterol homeostasis is regulated at least by LXR. These nuclear receptors are expressed as two isoforms, including the ubiquitous LXR β isoform and LXR α , which exhibits an expression restricted to cells with high cholesterol turnover (e.g., macrophages)^{104,108,112}. The LXR pathway is activated by intermediates from the cholesterol biosynthesis (e.g., desmosterol), endogenous oxidized cholesterol derivatives (called oxysterols, such as 22(R)-hydroxycholesterol [22RHC]), and synthetic agonists (e.g., T0901317 or GW3965)¹⁰⁴. LXR activation upregulates the expression of several genes involved in cholesterol homeostasis (*i.e.*, LXR target genes), including: *ABCA1*, *ABCG1*¹⁰⁵, and *APOE* (related to cholesterol efflux)^{106,113}, as well as the 'inducible degrader of the low-density lipoprotein receptor' (IDOL), preventing cholesterol uptake through LDLR/VLDLR degradation¹¹⁴. Overall, these mechanisms triggered by LXR activation participate in the decrease of intracellular cholesterol content. Again, the LXR pathway has been studied extensively in the regulation of macrophage functions, including cholesterol homeostasis and inflammatory responses, as well as apoptotic cell uptake (a process called efferocytosis)¹⁰⁸. However, the role of cholesterol and LXR begins only to be deciphered in PDC innate functions.

Inhibition of the mevalonate pathway (*i.e.*, *de novo* cholesterol biosynthesis) by statins (simvastatin and pitavastatin) blocks TLR7- and TLR9-induced type I IFN production by human PDC (Figure 3)¹¹⁵. This has been demonstrated with blood-derived PDC obtained from healthy donors, as well as from patients with SLE¹¹⁵. Statin treatment also inhibits TNF secretion by human PDC in response to either TLR7 (loxoribine) or TLR9 (CpGA) ligands¹¹⁵. These data have been confirmed *in vivo* using ssRNA Sendai virus¹¹⁵. Inhibition of *de novo* cholesterol synthesis by statins in PDC interferes with the p38 MAPK pathway, Akt and nuclear translocation of IRF7 (Figure 3)¹¹⁵. Finally, the inhibitory effect of statins has been tested *in vivo* and on mouse PDC, since treatment of C57BL/6 mouse with statins before triggering type I IFN production by ssRNA poly(U) injection decreases circulating IFN- α ¹¹⁵. Thus, the inhibition of cholesterol synthesis in PDC is associated with an anti-inflammatory response. This confirms the global anti-inflammatory effects of statins¹¹⁶.

human PDC and a PDC cell line CAL-1, a functional LXR pathway has been demonstrated, as attested by increased LXR target gene expression in response to three different LXR agonists (two synthetic agonists and an oxysterol, 22RHC that represents a more physiological LXR ligand). The activation of the LXR pathway in PDC reduces the pro-inflammatory cytokine secretion (IL-6 and TNF- α) induced by TLR7 triggering⁶. Moreover, these data obtained in human PDC from healthy donors⁶ and in leukemic PDC¹¹⁷ demonstrate that the LXR pathway interferes with TLR7-induced NF- κ B activation at different levels, including a transcriptional repression of p65 NF- κ B subunit and a reduced phosphorylation of this NF- κ B subunit (Figure 3)^{6,117}. Pretreatment of leukemic PDC with synthetic LXR agonists also reduces Akt and STAT5 phosphorylation in response to IL-3 (Figure 3)¹¹⁷. LXR stimulation in the PDC cell line CAL-1 increases cholesterol efflux *via* the upregulation of cholesterol transporters, such as ABCA1 (Figure 3)¹¹⁷. Although the cholesterol efflux was only tested using this CAL-1 PDC cell line¹¹⁷, upregulation of cholesterol transporters at mRNA and protein levels was also observed in human blood-derived PDC treated with LXR agonists⁶. Stimulation of cholesterol efflux by the addition of a cholesterol acceptor, APOA1, amplifies the effects of LXR activation in

leukemic PDC, including inhibition of the IL-3 signaling pathway (Akt and STAT5 phosphorylation) and cell survival (Figure 3)¹¹⁷. This confirms the previous data using statins¹¹⁵, and suggests that modifying cholesterol homeostasis in PDC can be useful to limit their detrimental role in pathological situations. Alteration of PDC survival after modification of intracellular cholesterol content using either statins¹¹⁵ or LXR agonists¹¹⁷ is only detected at highest concentrations (100 μ M). In addition, LXR activation in human PDC also increases microparticle internalization *via* the phosphatidylserine receptor (PtdSerR), BAI-1⁶. This contrasts with data obtained in macrophages in which LXR stimulation induces another PtdSerR, called Mer-TK (Mer tyrosine kinase)¹¹⁸. Nevertheless, this suggests that stimulation of PDC *via* the LXR pathway may improve their capacity to eliminate circulating pro-inflammatory microparticles. Triggering LXR pathway using LXR agonists before exposure to pro-inflammatory endothelial-derived microparticles prevents NF- κ B activation and pro-inflammatory cytokine production by human PDC⁶. This sustains an anti-inflammatory role of LXR agonists.

A discrepancy exists concerning type I IFN production after inhibition of cholesterol biosynthesis (using statins¹¹⁵) and the massive decrease of intracellular cholesterol content (using LXR agonists^{6,117}). Inhibition of type I IFN has been reported after statin treatment¹¹⁵, but not after cholesterol deprivation⁶. This may be due to a compensatory mechanism, since massively decreasing the pool size of synthesized cholesterol alone induces spontaneous type I IFN production associated with an antiviral immunity in bone marrow-derived macrophages¹¹⁹. This response occurs *via* the cGAS/STING/TBK1/IRF3 pathway¹¹⁹. Thus, LXR agonists could inhibit TLR7/9-mediated type I IFN by interfering with the mevalonate pathway (*i.e.*, *de novo* cholesterol synthesis), as statins did. Simultaneously, LXR agonists could stimulate type I IFN production as a result of a massive decrease in the intracellular cholesterol pool size. This compensatory mechanism could explain why IFN- α production is unaffected after LXR agonist treatment of PDC. Another difference between the effect of statins and LXR agonists lies in the inhibition of IRF7 (but not of NF- κ B phosphorylation by statins)¹¹⁵, whereas the activation of the LXR pathway in PDC blocks NF- κ B activation *via* several mechanisms^{6,117} (see above). Overall, the manipulation of cholesterol metabolism in PDC can be proposed to limit their pro-inflammatory functions.

4. Conclusions

Here, we summarize data currently available showing that several metabolic pathways are triggered in PDC by different stimuli, including pro-inflammatory signals (e.g., TLR7/9 ligands or endothelial-derived microparticles), as well as anti-inflammatory signals (e.g., platelet-derived microparticles). These pathways comprise: the mTOR signaling pathway, glycolysis, FAO coupled to OXPHOS, fatty acid synthesis and cholesterol metabolism (Table 1). All of these pathways are connected together, and they are globally necessary for efficient type I IFN production by PDC in response to TLR7/9-mediated activation. Few data are available, but it seems that induction of pro-inflammatory cytokines (e.g., TNF, IL-6 and IL-8) and costimulatory molecules (*i.e.*, CD80 or CD86) also need most of these metabolic pathways

(Table 1). On the contrary, alteration of cholesterol metabolism associated with decreased intracellular cholesterol content either after inhibition of *de novo* cholesterol synthesis or LXR activation inhibits the pro-inflammatory functions of PDC (Table 1). These data suggest that pharmacological manipulation of the host metabolism may be useful to reprogram altered PDC immune functions.

Since cellular metabolism is highly dependent on the microenvironment (oxygen availability and nutrients), changes in the local tissue microenvironment may modulate PDC innate immune functions. This modulation of metabolism may result from exogenous metabolites that diffuse passively or through transporters into the PDC. Among these metabolites, one may find ligands of lipid-activated nuclear receptors, such as LXR or PPAR^{3,108}.

Microenvironment and metabolic pathways may be modulated or controlled by microbiota. A recent study analyzed germ-free mice mono-colonized with each of the 53 human-resident bacterial species and the consequences of each bacterium on different immune cell subsets¹²⁰. Among these 53 bacteria, some bacteria were identified as modifying PDC frequencies in the colon and the small intestine¹²⁰. Among the genes for which their expression was correlated with PDC frequencies, the authors identified IFN-inducible signature transcripts, but also transcripts involved in lipid and protein metabolic pathways. Moreover, the *Hif1a* transcript coding for the metabolism regulator HIF-1 α was also associated with PDC frequencies¹²⁰. This suggests a connection between PDC frequencies in the gastro-intestinal tract and metabolic pathways and nutrients/metabolites provided by microbiota.

We discussed above the connection of metabolism with epigenetic regulation. While few data are available concerning epigenetic regulation of PDC innate immune functions, it has been shown that the inhibitor of histone deacetylase, valproic acid, alters human PDC functions, including the production of pro-inflammatory cytokines (IFN- α TNF and IL-6) in response to TLR9 ligand, CpGA¹²¹. Thus, it remains to be determined how metabolism may regulate epigenetic modification of DNA and histones in PDC.

Lastly, acute perturbations in intracellular lipid content, *via* for instance LXR activation, may also influence cell proliferation and survival by inducing significant ER stress¹⁰⁶. This cellular organelle is responsible for protein folding. The result of this ER stress is an accumulation of unfolded proteins. This pathway leads also to the expression of the transcription factor X-box binding protein 1 (XBP1), which induces lipid synthesis. XBP1 has been shown to regulate cDC infiltrating ovarian tumors; accumulation of lipids in the tumor-infiltrating cDC following ER stress and XBP1 activation reduces their ability to present antigens, and thus impairs anti-tumor T-cell responses¹²². Whether this may occur in infiltrating PDC remains to be analyzed. This may concern tumor-infiltrating PDC or PDC present in inflamed tissues. Nevertheless, PDC have been shown to express XBP1^{123,124}. This factor can be targeted with bortezomib, which disturbs ER homeostasis¹²⁴. This can be an additional way related to metabolism to block pro-inflammatory PDC functions. In conclusion, a

Table 1. Innate immune functions of plasmacytoid dendritic cells are modulated by or dependent on metabolic pathways.

Metabolic pathways	PDC	Stimulus used to stimulate PDC	Pharmacological agent used	Affected innate immune functions	References
mTOR signaling	human blood-sorted or mouse spleen-sorted PDC	CpGA (TLR9), attenuated yellow fever vaccine	rapamycin (inhibitor of mTORC1)	Type I IFN, IL-6, TNF- α	97
Glycolysis	human blood-sorted PDC	Gardiquimod (TLR7), influenza virus and Rhinovirus	2-deoxyglucose (inhibitor of glycolysis)	Type I IFN, expression of HLA-DR, CD80, and CD86	4
Fatty acid oxidation (FAO) coupled to OXPHOS	mouse PDC (sorted from FLT3 ligand-stimulated bone marrow cultures)	CpGA (TLR9)	etoxomir (inhibitor of carnitine palmitoyl transferase I)*	Type I IFN, TNF- α , IL-6, expression of CD86	5
	mouse PDC (sorted from FLT3 ligand-stimulated bone marrow cultures)	imiquimod (TLR7), LCMV	etoxomir	Type I IFN	5
	mouse PDC (sorted from FLT3 ligand-stimulated bone marrow cultures)	CpGA (TLR9)	GW6471 (inhibitor of PPAR α)	Type I IFN	5
Fatty acid synthesis	mouse PDC (sorted from FLT3 ligand-stimulated bone marrow cultures)	CpGA (TLR9)	TOFA (inhibitor of acetyl-CoA carboxylase), C75 (inhibitor of FASN)	Type I IFN, IL-6, TNF- α	5
Cholesterol metabolism	human blood-sorted PDC	CpGA (TLR9), loxoribine (TLR7), Sendai virus	simvastatin or pitavastatin (inhibitors of <i>de novo</i> cholesterol synthesis)	Type I IFN, TNF- α	115
	mouse PDC	ssRNA Poly(U)	simvastatin or pitavastatin	IFN- α	115
	human blood-sorted PDC	R848 (TLR7), endothelial-derived microparticles	GW3965, T0901317, 22RHC (LXR agonists)	TNF- α , IL-6	6

*This agent inhibits the entry of activated fatty acids into mitochondria for FAO. For abbreviations, please refer to the main text.

better understanding of PDC immunometabolism may help to limit the detrimental effect of these cells and increase their beneficial role in the future.

Author contributions

PS, AV, SP and AC critically read, analysed and discussed the literature and conceived the outline of the manuscript. PS wrote the manuscript. SP, AV and AC edited the manuscript and provided valuable discussions and criticism.

Competing interests

The authors declare that they have no competing interests.

Grant information

The work in this field is supported by the Agence Nationale de la Recherche (LabEx LipSTIC; ANR-11-LABX-0021), and the Conseil Régional de Bourgogne Franche-Comté ("soutien au LabEx LipSTIC" 2016).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Acknowledgements

We would like to thank Sarah Odrien for her help in editing our manuscript, and the members of our laboratory for their work.

References

1. O'Neill LA, Pearce EJ: **Immunometabolism governs dendritic cell and macrophage function.** *J Exp Med.* 2016; 213(1): 15–23.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. O'Neill LA, Kishton RJ, Rathmell J: **A guide to immunometabolism for immunologists.** *Nat Rev Immunol.* 2016; 16(9): 553–565.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Pearce EJ, Everts B: **Dendritic cell metabolism.** *Nat Rev Immunol.* 2015; 15(1): 18–29.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Bajwa G, DeBerardinis RJ, Shao B, *et al.*: **Cutting Edge: Critical Role of Glycolysis in Human Plasmacytoid Dendritic Cell Antiviral Responses.** *J Immunol.* 2016; 196(5): 2004–2009.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
5. Wu D, Sanin DE, Everts B, *et al.*: **Type 1 Interferons Induce Changes in Core Metabolism that are Critical for Immune Function.** *Immunity.* 2016; 44(6): 1325–1336.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. Ceroi A, Delettre FA, Marotel C, *et al.*: **The anti-inflammatory effects of platelet-derived microparticles in human plasmacytoid dendritic cells involve liver X receptor activation.** *Haematologica.* 2016; 101(3): e72–76.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Swiecki M, Colonna M: **The multifaceted biology of plasmacytoid dendritic cells.** *Nat Rev Immunol.* 2015; 15(8): 471–485.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Saxton RA, Sabatini DM: **mTOR Signaling in Growth, Metabolism, and Disease.** *Cell.* 2017; 168(6): 960–976.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Weichhart T, Hengstschläger M, Linke M: **Regulation of innate immune cell function by mTOR.** *Nat Rev Immunol.* 2015; 15(10): 599–614.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Sharma MD, Hou DY, Liu Y, *et al.*: **Indoleamine 2,3-dioxygenase controls conversion of Foxp3⁺ Tregs to TH17-like cells in tumor-draining lymph nodes.** *Blood.* 2009; 113(24): 6102–6111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. Pearce EL, Pearce EJ: **Metabolic pathways in immune cell activation and quiescence.** *Immunity.* 2013; 38(4): 633–643.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Audano M, Ferrari A, Fiorino E, *et al.*: **Energizing Genetics and Epi-genetics: Role in the Regulation of Mitochondrial Function.** *Curr Genomics.* 2014; 15(6): 436–456.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Li W, Sivakumar R, Titov AA, *et al.*: **Metabolic Factors that Contribute to Lupus Pathogenesis.** *Crit Rev Immunol.* 2016; 36(1): 75–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Williams M, Ginhoux F, Jakubick C, *et al.*: **Dendritic cells, monocytes and macrophages: a unified nomenclature based on ontogeny.** *Nat Rev Immunol.* 2014; 14(8): 571–578.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Cella M, Jarrossay D, Facchetti F, *et al.*: **Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon.** *Nat Med.* 1999; 5(8): 919–923.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Siegal FP, Kadowaki N, Shodell M, *et al.*: **The nature of the principal type 1 interferon-producing cells in human blood.** *Science.* 1999; 284(5421): 1835–1837.
[PubMed Abstract](#) | [Publisher Full Text](#)
17. Asselin-Paturel C, Boonstra A, Dalod M, *et al.*: **Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology.** *Nat Immunol.* 2001; 2(12): 1144–1150.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Nakano H, Yanagita M, Gunn MD: **CD11c⁺B220⁺Gr-1⁺ cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells.** *J Exp Med.* 2001; 194(8): 1171–1178.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Ferrero I, Held W, Wilson A, *et al.*: **Mouse CD11c⁺B220⁺Gr1⁺ plasmacytoid dendritic cells develop independently of the T-cell lineage.** *Blood.* 2002; 100(8): 2852–2857.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Martín P, Del Hoyo GM, Anjère F, *et al.*: **Characterization of a new subpopulation of mouse CD8 α ⁺B220⁺ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential.** *Blood.* 2002; 100(2): 383–390.
[PubMed Abstract](#) | [Publisher Full Text](#)
21. Robbins SH, Walzer T, Dembéli D, *et al.*: **Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling.** *Genome Biol.* 2008; 9(1): R17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Liu K, Victora GD, Schwickert TA, *et al.*: **In vivo analysis of dendritic cell development and homeostasis.** *Science.* 2009; 324(5925): 392–397.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Contractor N, Louten J, Kim L, *et al.*: **Cutting edge: Peyer's patch plasmacytoid dendritic cells (pDCs) produce low levels of type I interferons: possible role for IL-10, TGF β , and prostaglandin E₂ in conditioning a unique mucosal pDC phenotype.** *J Immunol.* 2007; 179(5): 2690–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Li HS, Gelbard A, Martinez GJ, *et al.*: **Cell-intrinsic role for IFN- α -STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response.** *Blood.* 2011; 118(14): 3879–3889.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
25. Sisirak V, Vey N, Vanbervliet B, *et al.*: **CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.** *Blood.* 2011; 118(19): 5130–5140.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. de Heer HJ, Hammad H, Soullé T, *et al.*: **Essential role of lung plasmacytoid dendritic cells in preventing asthmatic reactions to harmless inhaled antigen.** *J Exp Med.* 2004; 200(1): 89–98.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
27. Tokita D, Sumpter TL, Raimondi G, *et al.*: **Poor allostimulatory function of liver plasmacytoid DC is associated with pro-apoptotic activity, dependent on regulatory T cells.** *J Hepatol.* 2008; 49(6): 1008–1018.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
28. Matta BM, Castellana A, Thomson AW: **Tolerogenic plasmacytoid DC.** *Eur J Immunol.* 2010; 40(10): 2667–2676.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Okada T, Lian ZX, Naiki M, *et al.*: **Murine thymic plasmacytoid dendritic cells.** *Eur J Immunol.* 2003; 33(4): 1012–1019.
[PubMed Abstract](#) | [Publisher Full Text](#)
30. Li J, Park J, Foss D, *et al.*: **Thymus-homing peripheral dendritic cells constitute two of the three major subsets of dendritic cells in the steady-state thymus.** *J Exp Med.* 2009; 206(3): 607–622.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
31. Hadeiba H, Lahl K, Edalati A, *et al.*: **Plasmacytoid dendritic cells transport peripheral antigens to the thymus to promote central tolerance.** *Immunity.* 2012; 36(3): 438–450.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
32. Vermi W, Riboldi E, Wittamer V, *et al.*: **Role of ChemR23 in directing the migration of myeloid and plasmacytoid dendritic cells to lymphoid organs and inflamed skin.** *J Exp Med.* 2005; 201(4): 509–515.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Salio M, Cella M, Vermi W, *et al.*: **Plasmacytoid dendritic cells prime IFN- γ -secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions.** *Eur J Immunol.* 2003; 33(4): 1052–62.
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Hartmann E, Wollenberg B, Rothenfusser S, *et al.*: **Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer.** *Cancer Res.* 2003; 63(19): 6478–87.
[PubMed Abstract](#)
35. Treilleux I, Blay JY, Bendriss-Vermare N, *et al.*: **Dendritic cell infiltration and prognosis of early stage breast cancer.** *Clin Cancer Res.* 2004; 10(22): 7466–74.
[PubMed Abstract](#) | [Publisher Full Text](#)
36. Faget J, Bendriss-Vermare N, Gobert M, *et al.*: **ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4⁺ T cells.** *Cancer Res.* 2012; 72(23): 6130–41.
[PubMed Abstract](#) | [Publisher Full Text](#)
37. Ghirelli C, Reyat F, Jeanmougin M, *et al.*: **Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes.** *Cancer Res.* 2015; 75(14): 2775–87.
[PubMed Abstract](#) | [Publisher Full Text](#)
38. Labidi-Galy SI, Sisirak V, Meeus P, *et al.*: **Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer.** *Cancer Res.* 2011; 71(16): 5423–34.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Labidi-Galy SI, Treilleux I, Goddard-Leon S, *et al.*: **Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.** *Oncoimmunology.* 2012; 1(3): 380–382.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
40. Conrad C, Gregorio J, Wang YH, *et al.*: **Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3⁺ T-regulatory cells.** *Cancer Res.* 2012; 72(20): 5240–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Gilliet M, Cao W, Liu YJ: **Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases.** *Nat Rev Immunol.* 2008; 8(8): 594–606.
[PubMed Abstract](#) | [Publisher Full Text](#)
42. Reizis B, Bunin A, Ghosh HS, *et al.*: **Plasmacytoid dendritic cells: recent progress and open questions.** *Annu Rev Immunol.* 2011; 29: 163–183.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Cervantes-Barragan L, Lewis KL, Firner S, *et al.*: **Plasmacytoid dendritic cells control T-cell response to chronic viral infection.** *Proc Natl Acad Sci U S A.*

- 2012; **109**(8): 3012–3017.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Swiecki M, Gilfillan S, Vermi W, *et al.*: Plasmacytoid dendritic cell ablation impacts early interferon responses and antiviral NK and CD8⁺ T cell accrual. *Immunity*. 2010; **33**(6): 955–966.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Takagi H, Fukaya T, Ezumi K, *et al.*: Plasmacytoid dendritic cells are crucial for the initiation of inflammation and T cell immunity *in vivo*. *Immunity*. 2011; **35**(6): 958–971.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Pelka K, Latz E: IRF5, IRF8, and IRF7 in human pDCs - the good, the bad, and the insignificant? *Eur J Immunol*. 2013; **43**(7): 1693–1697.
[PubMed Abstract](#) | [Publisher Full Text](#)
 47. Kadowaki N, Ho S, Antonenko S, *et al.*: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. *J Exp Med*. 2001; **194**(6): 863–869.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. Diebold SS, Kaisho T, Hemmi H, *et al.*: Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. *Science*. 2004; **303**(5663): 1529–1531.
[PubMed Abstract](#) | [Publisher Full Text](#)
 49. Moynagh PN: TLR signalling and activation of IRFs: revisiting old friends from the NF-kappaB pathway. *Trends Immunol*. 2005; **26**(9): 469–476.
[PubMed Abstract](#) | [Publisher Full Text](#)
 50. Barrat FJ, Meeker T, Gregorio J, *et al.*: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. *J Exp Med*. 2005; **202**(8): 1131–1139.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. Lande R, Gregorio J, Facchinetti V, *et al.*: Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. *Nature*. 2007; **449**(7162): 564–569.
[PubMed Abstract](#) | [Publisher Full Text](#)
 52. Ganguly D, Chamilos G, Lande R, *et al.*: Self-RNA-antimicrobial peptide complexes activate human dendritic cells through TLR7 and TLR8. *J Exp Med*. 2009; **206**(9): 1983–1994.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. Honda K, Yanai H, Negishi H, *et al.*: IRF-7 is the master regulator of type-I interferon-dependent immune responses. *Nature*. 2005; **434**(7034): 772–777.
[PubMed Abstract](#) | [Publisher Full Text](#)
 54. Guiducci C, Ghirelli C, Marloie-Provost MA, *et al.*: PI3K is critical for the nuclear translocation of IRF-7 and type I IFN production by human plasmacytoid dendritic cells in response to TLR activation. *J Exp Med*. 2008; **205**(2): 315–322.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 55. Bauer M, Redecke V, Ellwart JW, *et al.*: Bacterial CpG-DNA triggers activation and maturation of human CD11c⁺, CD123⁺ dendritic cells. *J Immunol*. 2001; **166**(8): 5000–5007.
[PubMed Abstract](#) | [Publisher Full Text](#)
 56. Angelot F, Seillès E, Bichlé S, *et al.*: Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: potential implications in inflammatory diseases. *Haematologica*. 2009; **94**(11): 1502–1512.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 57. Piqueras B, Connolly J, Freitas H, *et al.*: Upon viral exposure, myeloid and plasmacytoid dendritic cells produce 3 waves of distinct chemokines to recruit immune effectors. *Blood*. 2006; **107**(7): 2613–2618.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Kerkmann M, Rothenfusser S, Hornung V, *et al.*: Activation with CpG-A and CpG-B oligonucleotides reveals two distinct regulatory pathways of type I IFN synthesis in human plasmacytoid dendritic cells. *J Immunol*. 2003; **170**(9): 4465–4474.
[PubMed Abstract](#) | [Publisher Full Text](#)
 59. Tian J, Avalos AM, Mao SY, *et al.*: Toll-like receptor 9-dependent activation by DNA-containing immune complexes is mediated by HMGB1 and RAGE. *Nat Immunol*. 2007; **8**(5): 487–496.
[PubMed Abstract](#) | [Publisher Full Text](#)
 60. Dumitriu IE, Baruah P, Bianchi ME, *et al.*: Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. *Eur J Immunol*. 2005; **35**(7): 2184–2190.
[PubMed Abstract](#) | [Publisher Full Text](#)
 61. Rovere-Querini P, Capobianco A, Scaffidi P, *et al.*: HMGB1 is an endogenous immune adjuvant released by necrotic cells. *EMBO Rep*. 2004; **5**(8): 825–830.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 62. Garcia-Romo GS, Caielli S, Vega B, *et al.*: Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. *Sci Transl Med*. 2011; **3**(73): 73ra20.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 63. Lande R, Ganguly D, Facchinetti V, *et al.*: Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. *Sci Transl Med*. 2011; **3**(73): 73ra19.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Duffau P, Seneschal J, Nicco C, *et al.*: Platelet CD154 potentiates interferon-alpha secretion by plasmacytoid dendritic cells in systemic lupus erythematosus. *Sci Transl Med*. 2010; **2**(47): 47ra63.
[PubMed Abstract](#) | [Publisher Full Text](#)
 65. Broz P, Monack DM: Newly described pattern recognition receptors team up against intracellular pathogens. *Nat Rev Immunol*. 2013; **13**(8): 551–565.
[PubMed Abstract](#) | [Publisher Full Text](#)
 66. Bonnefoy F, Perruche S, Couturier M, *et al.*: Plasmacytoid dendritic cells play a major role in apoptotic leukocyte-induced immune modulation. *J Immunol*. 2011; **186**(10): 5696–5705.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Ochando JC, Homma C, Yang Y, *et al.*: Alloantigen-presenting plasmacytoid dendritic cells mediate tolerance to vascularized grafts. *Nat Immunol*. 2006; **7**(6): 652–662.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Hadeiba H, Sato T, Habtezion A, *et al.*: CCR9 expression defines tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host disease. *Nat Immunol*. 2008; **9**(11): 1253–60.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 69. Goubier A, Dubois B, Gheit H, *et al.*: Plasmacytoid dendritic cells mediate oral tolerance. *Immunity*. 2008; **29**(3): 464–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 70. Munn DH, Sharma MD, Hou D, *et al.*: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. *J Clin Invest*. 2004; **114**(2): 280–290.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 71. Sharma MD, Baban B, Chandler P, *et al.*: Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. *J Clin Invest*. 2007; **117**(9): 2570–2582.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 72. Mellor AL, Baban B, Chandler PR, *et al.*: Cutting edge: CpG oligonucleotides induce splenic CD19⁺ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. *J Immunol*. 2005; **175**(9): 5601–5605.
[PubMed Abstract](#) | [Publisher Full Text](#)
 73. Pallotta MT, Orabona C, Volpi C, *et al.*: Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. *Nat Immunol*. 2011; **12**(9): 870–878.
[PubMed Abstract](#) | [Publisher Full Text](#)
 74. Cao W, Rosen DB, Ito T, *et al.*: Plasmacytoid dendritic cell-specific receptor ILT7-Fc epsilonRI gamma inhibits Toll-like receptor-induced interferon production. *J Exp Med*. 2006; **203**(6): 1399–1405.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 75. Dzionek A, Sohma Y, Nagafune J, *et al.*: BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. *J Exp Med*. 2001; **194**(12): 1823–1834.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 76. Saas P, Perruche S: Functions of TGF- β -exposed plasmacytoid dendritic cells. *Crit Rev Immunol*. 2012; **32**(6): 529–553.
[PubMed Abstract](#) | [Publisher Full Text](#)
 77. Grouard G, Risoan MC, Filgueira L, *et al.*: The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. *J Exp Med*. 1997; **185**(6): 1101–1111.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 78. Ghirelli C, Zollinger R, Soumelis V: Systematic cytokine receptor profiling reveals GM-CSF as a novel TLR-independent activator of human plasmacytoid dendritic cells. *Blood*. 2010; **115**(24): 5037–5040.
[PubMed Abstract](#) | [Publisher Full Text](#)
 79. Chistiakov DA, Orekhov AN, Sobenin IA, *et al.*: Plasmacytoid dendritic cells: development, functions, and role in atherosclerotic inflammation. *Front Physiol*. 2014; **5**: 279.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 80. Fritsch SD, Weichhart T: Effects of Interferons and Viruses on Metabolism. *Front Immunol*. 2016; **7**: 630.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 81. Banchereau J, Pascual V: Type I interferon in systemic lupus erythematosus and other autoimmune diseases. *Immunity*. 2006; **25**(3): 383–392.
[PubMed Abstract](#) | [Publisher Full Text](#)
 82. Diana J, Simoni Y, Furio L, *et al.*: Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. *Nat Med*. 2013; **19**(1): 65–73.
[PubMed Abstract](#) | [Publisher Full Text](#)
 83. van Bon L, Affandi AJ, Broen J, *et al.*: Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. *N Engl J Med*. 2014; **370**(5): 433–443.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 84. Nestle FO, Conrad C, Tun-Kyi A, *et al.*: Plasmacytoid dendritic cells initiate psoriasis through interferon-alpha production. *J Exp Med*. 2005; **202**(1): 135–143.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 85. Millet A, Martin KR, Bonnefoy F, *et al.*: Proteinase 3 on apoptotic cells disrupts immune silencing in autoimmune vasculitis. *J Clin Invest*. 2015; **125**(11): 4107–4121.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 86. Bossard C, Malard F, Arbez J, *et al.*: Plasmacytoid dendritic cells and Th17 immune response contribution in gastrointestinal acute graft-versus-host disease. *Leukemia*. 2012; **26**(7): 1471–1474.
[PubMed Abstract](#) | [Publisher Full Text](#)

87. Malard F, Bossard C, Brissot E, *et al.*: **Increased plasmacytoid dendritic cells and ROR γ t-expressing immune effectors in cutaneous acute graft-versus-host disease.** *J Leukoc Biol.* 2013; **94**(6): 1337–1343.
[PubMed Abstract](#) | [Publisher Full Text](#)
88. Döring Y, Zernecke A: **Plasmacytoid dendritic cells in atherosclerosis.** *Front Physiol.* 2012; **3**: 230.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
89. Soumelis V, Scott I, Gheysa F, *et al.*: **Depletion of circulating natural type 1 interferon-producing cells in HIV-infected AIDS patients.** *Blood.* 2001; **98**(4): 906–912.
[PubMed Abstract](#) | [Publisher Full Text](#)
90. Szabo G, Dolganiuc A: **The role of plasmacytoid dendritic cell-derived IFN alpha in antiviral immunity.** *Crit Rev Immunol.* 2008; **28**(1): 61–94.
[PubMed Abstract](#) | [Publisher Full Text](#)
91. Tsukamoto N, Okada S, Onami Y, *et al.*: **Impairment of plasmacytoid dendritic cells for IFN production by the ligand for immunoglobulin-like transcript 7 expressed on human cancer cells.** *Clin Cancer Res.* 2009; **15**(18): 5733–43.
[PubMed Abstract](#) | [Publisher Full Text](#)
92. Sisirak V, Faget J, Gobert M, *et al.*: **Impaired IFN- α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.** *Cancer Res.* 2012; **72**(20): 5188–97.
[PubMed Abstract](#) | [Publisher Full Text](#)
93. Chang CH, Qiu J, O'Sullivan D, *et al.*: **Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression.** *Cell.* 2015; **162**(6): 1229–41.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
94. Robey RB, Weisz J, Kuemmerle NB, *et al.*: **Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis?** *Carcinogenesis.* 2015; **36**(Suppl 1): S203–31.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
95. Buck MD, Sowell RT, Kaech SM, *et al.*: **Metabolic Instruction of Immunity.** *Cell.* 2017; **169**(4): 570–586.
[PubMed Abstract](#) | [Publisher Full Text](#)
96. Costa-Mattioli M, Sonenberg N: **RAPping production of type I interferon in pDCs through mTOR.** *Nat Immunol.* 2008; **9**(10): 1097–1099.
[PubMed Abstract](#) | [Publisher Full Text](#)
97. Cao W, Manicassamy S, Tang H, *et al.*: **Toll-like receptor-mediated induction of type I interferon in plasmacytoid dendritic cells requires the rapamycin-sensitive PI(3)K-mTOR-p70S6K pathway.** *Nat Immunol.* 2008; **9**(10): 1157–1164.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
98. Corcoran SE, O'Neill LA: **HIF1 α and metabolic reprogramming in inflammation.** *J Clin Invest.* 2016; **126**(10): 3699–3707.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
99. Van Krinks CH, Matyszak MK, Gaston JS: **Characterization of plasmacytoid dendritic cells in inflammatory arthritis synovial fluid.** *Rheumatology (Oxford).* 2004; **43**(4): 453–460.
[PubMed Abstract](#) | [Publisher Full Text](#)
100. Lande R, Giacomini E, Serafini B, *et al.*: **Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis.** *J Immunol.* 2004; **173**(4): 2815–2824.
[PubMed Abstract](#) | [Publisher Full Text](#)
101. Cavanagh LL, Boyce A, Smith L, *et al.*: **Rheumatoid arthritis synovium contains plasmacytoid dendritic cells.** *Arthritis Res Ther.* 2005; **7**(2): R230–240.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
102. Arimura K, Takagi H, Uto T, *et al.*: **Crucial role of plasmacytoid dendritic cells in the development of acute colitis through the regulation of intestinal inflammation.** *Mucosal Immunol.* 2017; **10**(4): 957–970.
[PubMed Abstract](#) | [Publisher Full Text](#)
103. Lund JM, Alexopoulou L, Sato A, *et al.*: **Recognition of single-stranded RNA viruses by Toll-like receptor 7.** *Proc Natl Acad Sci U S A.* 2004; **101**(15): 5598–5603.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
104. Hong C, Tontonoz P: **Liver X receptors in lipid metabolism: opportunities for drug discovery.** *Nat Rev Drug Discov.* 2014; **13**(6): 433–444.
[PubMed Abstract](#) | [Publisher Full Text](#)
105. Wójcicka G, Jamroz-Wisniewska A, Horoszewicz K, *et al.*: **Liver X receptors (LXRs). Part I: structure, function, regulation of activity, and role in lipid metabolism.** *Postepy Hig Med Dosw (Online).* 2007; **61**: 736–759.
[PubMed Abstract](#)
106. Kidani Y, Bensinger SJ: **Liver X receptor and peroxisome proliferator-activated receptor as integrators of lipid homeostasis and immunity.** *Immunol Rev.* 2012; **249**(1): 72–83.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
107. Rakhshandehroo M, Knoch B, Muller M, *et al.*: **Peroxisome proliferator-activated receptor alpha target genes.** *PPAR Res.* 2010; **2010**; pii: 612089.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
108. Kiss M, Czimmerer Z, Nagy L: **The role of lipid-activated nuclear receptors in shaping macrophage and dendritic cell function: From physiology to pathology.** *J Allergy Clin Immunol.* 2013; **132**(2): 264–286.
[PubMed Abstract](#) | [Publisher Full Text](#)
109. Horton JD, Goldstein JL, Brown MS: **SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver.** *J Clin Invest.* 2002; **109**(9): 1125–1131.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
110. Ikonen E: **Cellular cholesterol trafficking and compartmentalization.** *Nat Rev Mol Cell Biol.* 2008; **9**(2): 125–138.
[PubMed Abstract](#) | [Publisher Full Text](#)
111. Oram JF, Vaughan AM: **ATP-Binding cassette cholesterol transporters and cardiovascular disease.** *Circ Res.* 2006; **99**(10): 1031–1043.
[PubMed Abstract](#) | [Publisher Full Text](#)
112. Im SS, Osborne TF: **Liver x receptors in atherosclerosis and inflammation.** *Circ Res.* 2011; **108**(8): 996–1001.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
113. Dove DE, Linton MF, Fazio S: **ApoE-mediated cholesterol efflux from macrophages: separation of autocrine and paracrine effects.** *Am J Physiol Cell Physiol.* 2005; **288**(3): C586–592.
[PubMed Abstract](#) | [Publisher Full Text](#)
114. Hong C, Duit S, Jalonen P, *et al.*: **The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.** *J Biol Chem.* 2010; **285**(26): 19720–19726.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
115. Amuro H, Ito T, Miyamoto R, *et al.*: **Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production.** *Arthritis Rheum.* 2010; **62**(7): 2073–2085.
[PubMed Abstract](#) | [Publisher Full Text](#)
116. Bu DX, Griffin G, Lichtman AH: **Mechanisms for the anti-inflammatory effects of statins.** *Curr Opin Lipidol.* 2011; **22**(3): 165–170.
[PubMed Abstract](#) | [Publisher Full Text](#)
117. Ceroi A, Masson D, Roggy A, *et al.*: **LXR agonist treatment of blastic plasmacytoid dendritic cell neoplasm restores cholesterol efflux and triggers apoptosis.** *Blood.* 2016; **128**(23): 2694–2707.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
118. A-Gonzalez N, Bensinger SJ, Hong C, *et al.*: **Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR.** *Immunity.* 2009; **31**(2): 245–258.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
119. York AG, Williams KJ, Argus JP, *et al.*: **Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling.** *Cell.* 2015; **163**(7): 1716–1729.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
120. Geva-Zatorsky N, Sefik E, Kua L, *et al.*: **Mining the Human Gut Microbiota for Immunomodulatory Organisms.** *Cell.* 2017; **168**(5): 928–943.e911.
[PubMed Abstract](#) | [Publisher Full Text](#)
121. Arbez J, Lamarthee B, Gaugler B, *et al.*: **Histone deacetylase inhibitor valproic acid affects plasmacytoid dendritic cells phenotype and function.** *Immunobiology.* 2014; **219**(8): 637–643.
[PubMed Abstract](#) | [Publisher Full Text](#)
122. Cubillos-Ruiz JR, Bettigole SE, Glimcher LH: **Molecular Pathways: Immunosuppressive Roles of IRE1 α -XBP1 Signaling in Dendritic Cells of the Tumor Microenvironment.** *Clin Cancer Res.* 2016; **22**(9): 2121–2126.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
123. Iwakoshi NN, Pypaert M, Glimcher LH: **The transcription factor XBP-1 is essential for the development and survival of dendritic cells.** *J Exp Med.* 2007; **204**(10): 2267–75.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
124. Hirai M, Kadowaki N, Kitawaki T, *et al.*: **Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis.** *Blood.* 2011; **117**(2): 500–509.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 2

Reviewer Report 24 July 2017

<https://doi.org/10.5256/f1000research.12930.r23752>

© 2017 Pearce E et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Edward J. Pearce

Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Katarzyna Grzes

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 05 July 2017

<https://doi.org/10.5256/f1000research.12930.r23750>

© 2017 Bendriss-Vermare N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nathalie Bendriss-Vermare

Team Caux (French National Institute of Health and Medical Research) INSERM U1052/CNRS 5286 (French National Center for Scientific Research), Cancer Research Centre of Lyon (CRCL), Lyon, France

The authors have rigorously addressed each aspect of my comments. This revised manuscript is now suitable for indexing.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Oncoimmunology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Version 1

Reviewer Report 12 May 2017

<https://doi.org/10.5256/f1000research.12232.r22647>

© 2017 Pearce E et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Edward J. Pearce

Department of Immunometabolism, Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

Katarzyna Grzes

Max Planck Institute of Immunobiology and Epigenetics, Freiburg, Germany

In the review by Saas et al., the authors discussed the collective knowledge of the metabolic status of pDC. Despite the fact that data on this subject are rather scarce, the authors prepared an interesting manuscript. They also included a section about the role and function of pDC which created a more comprehensive source of information.

Comments:

- Abstract needs more clarity, i.e. "Recent data support the idea that the glycolytic pathway (or glycolysis), as well as lipid metabolism (including both cholesterol and fatty acid metabolism) may impact some innate immune functions of PDC or may be involved in these functions after Toll-like receptor (TLR) 7/9 triggering. Some differences may be related to the origin of PDC (human *versus* mouse PDC or blood-sorted *versus* FLT3 ligand stimulated-bone marrow-sorted PDC)." If the authors want to keep this in the abstract they should probably mention what the differences are.
- Please consider rearranging and shortening the Introduction to avoid repetition.
- When talking about the role of mTOR in pDCs, I think there is no need for a detailed introduction to mTOR – there are many recent authoritative reviews on this subject. The authors should refer to one of these. For example, a review by David Sabatini.
- The language of the review can be confusing at times. For example, the following sentence should probably be deleted for the sake of clarity: "After differentiation in the bone marrow, PDC are released into the bloodstream for homing to different lymphoid tissues. Thus, PDC isolated from blood of healthy donors or patients consist in PDC migrating to these tissues."

- The authors should make an attempt to reference original work rather than other reviews. For example, "Localizations of PDC in other lymphoid organs, such as Peyer's patches of the gut". Instead of Li et al. (2011)¹, please cite the paper by Contractor et al.(2007)².

References

1. Li HS, Gelbard A, Martinez GJ, Esashi E, et al.: Cell-intrinsic role for IFN- α -STAT1 signals in regulating murine Peyer patch plasmacytoid dendritic cells and conditioning an inflammatory response. *Blood*. 2011; **118** (14): 3879-89 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Contractor N, Louten J, Kim L, Biron C, et al.: Cutting Edge: Peyer's Patch Plasmacytoid Dendritic Cells (pDCs) Produce Low Levels of Type I Interferons: Possible Role for IL-10, TGF β , and Prostaglandin E2 in Conditioning a Unique Mucosal pDC Phenotype. *The Journal of Immunology*. 2007; **179** (5): 2690-2694 [Publisher Full Text](#)

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Partly

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Immunometabolism

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response (F1000Research Advisory Board Member) 15 Jun 2017

Philippe Saas, Inserm, UMR1098, Besançon, France

We thank the reviewers for their constructive comments. We appreciate greatly these comments and we have tried to answer to them. Please find below a point by point response to the reviewers' comments.

1. Abstract needs more clarity, i.e. "Recent data support the idea that the glycolytic pathway (or glycolysis), as well as lipid metabolism (including both cholesterol and fatty acid metabolism)

may impact some innate immune functions of PDC or may be involved in these functions after Toll-like receptor (TLR) 7/9 triggering. Some differences may be related to the origin of PDC (human versus mouse PDC or blood-sorted versus FLT3 ligand stimulated-bone marrow-sorted PDC)." If the authors want to keep this in the abstract they should probably mention what the differences are.

We agree with this comment. It is similar to the first comment of reviewer #2. We have deleted the following sentence: "Some differences may be related to the origin of PDC (human versus mouse PDC or blood-sorted versus FLT3 ligand stimulated-bone marrow-sorted PDC)."

2. Please consider rearranging and shortening the Introduction to avoid repetition.

We prefer to keep the repetition for readers not involved in the fields of either metabolism or PDC. We also want to emphasize that few data are available for PDC compared to macrophages or conventional dendritic cells.

3. When talking about the role of mTOR in pDCs, I think there is no need for a detailed introduction to mTOR – there are many recent authoritative reviews on this subject. The authors should refer to one of these. For example, a review by David Sabatini.

We have quoted a review by David Sabatini (Ref# 8).

4. The language of the review can be confusing at time. For example, the following sentence should probably be deleted for the sake of clarity: "After differentiation in the bone marrow, PDC are released into the bloodstream for homing to different lymphoid tissues. Thus, PDC isolated from blood of healthy donors or patients consist in PDC migrating to these tissues."

We have changed the beginning of this paragraph. We have deleted the second sentence since it corresponded to a repetition of the previous paragraph and we have modified a little bit the mentioned sentences.

5. The authors should make an attempt to reference original work rather than other reviews. For example, "Localizations of PDC in other lymphoid organs, such as Peyer's patches of the gut". Instead of Li et al. (2011)¹, please cite the paper by Contractor et al. (2007)².

Now, we have quoted the paper by Contractor et al. (2007) in addition to those by Li et al. (2011). Both papers are original works. We have also followed the recommendation to quote original works when references on PDC infiltrating tumors have been added.

Competing Interests: No competing interests were declared.

Reviewer Report 11 May 2017

<https://doi.org/10.5256/f1000research.12232.r21755>

© 2017 Bendriss-Vermare N. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Nathalie Bendriss-Vermare

Team Caux (French National Institute of Health and Medical Research) INSERM U1052/CNRS 5286 (French National Center for Scientific Research), Cancer Research Centre of Lyon (CRCL), Lyon, France

This review provides a balanced and comprehensive overview of the latest discoveries about the role of metabolism in plasmacytoid dendritic cell innate functions. This is a very original topic based on recent data supporting the idea that the glycolytic pathway as well as lipid metabolism may modulate the production of type I IFN by pDC or may be involved in this function after TLR7/9 triggering. In addition, this review provides new clues on how these metabolic pathways may be harnessed in pathophysiological contexts where pDC play a detrimental role.

This review has a comprehensive view of all relevant literature in the field and summarized very well the fundamental concepts, but there are some minor concerns that need to be addressed as below.

1. Abstract is clearly written, but the text could be reduced by omitting the section about the differences related to the origin of pDC.
2. Page 3: PRR stands for Pattern (but not Pathogen) Recognition Receptors
3. Page 3: I would suggest to add that i) human pDC are usually identified as CD4⁺ CD303⁺ CD123^{high} and CD11c^{negative} (to highlight the difference with mouse pDC that are CD11c^{low}), ii) *irf7* is also a master genes that is shared between human and mouse pDC, iii) CD317 (known as BST2, PDCA1).
4. Page 5: the list of references related to the regulatory functions of pDC is too short. Some major articles should be added (Ochando 2006, Goubier 2008, Hadeiba 2008, Irla 2010, etc...).
5. Page 5 paragraph 2.4: when the authors discuss the role of pDC in diseases, they focus on autoimmune disorders, GVHD, atherosclerosis, and chronic viral infections but cancer was omitted. Yet, metabolic pathways are deeply altered in the context of cancer and I would assume that the innate functions of pDC would be modulated by the metabolic changes occurring in tumor microenvironment. This needs to be discussed.
6. Page 7: when the authors discuss the role of glycolysis on pDC functions upon TLR7 triggering, it is not clear whether this is a global regulation of the transcription or whether this is specific of genes related to type I IFN pathway.
7. Page 10: it is not very interesting but not clear to me how the massive decrease of intracellular cholesterol content is connected to the activation of STING/cGAS pathway leading to spontaneous type I IFN production in macrophages. This should be clarified.

8. The figures nicely support and illustrate the main text of the review. Nevertheless, I would suggest to add a table summarizing the main effects of each metabolic pathway on pDC biology by comparing human versus mouse and TLR7 versus TLR9 stimulation.

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Yes

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Oncoimmunology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response (F1000Research Advisory Board Member) 15 Jun 2017

Philippe Saas, Inserm, UMR1098, Besançon, France

We thank the reviewer for her constructive comments. We appreciate greatly these comments and we have tried to answer to them. Please find below a point by point response to the reviewer's comments.

1. Abstract is clearly written, but the text could be reduced by omitting the section about the differences related to the origin of pDC.

We have modified the abstract accordingly.

2. Page 3: PRR stands for Pattern (but not Pathogen) Recognition Receptors

This is true. We have corrected this abbreviation.

3. Page 3: I would suggest to add that i) human pDC are usually identified as CD4+ CD303+ CD123high and CD11cnegative (to highlight the difference with mouse pDC that are CD11clow), ii) irf7 is also a master genes that is shared between human and mouse pDC, iii) CD317 (known as BST2, PDCA1).

We have added these features according to the reviewer's suggestions.

4. Page 5: the list of references related to the regulatory functions of pDC is too short. Some major articles should be added (Ochando 2006, Goubier 2008, Hadeiba 2008, Irla 2010, etc...).

We have not expanded too much this part of the text. We have quoted the original work of Ochando 2006, Goubier 2008, and Hadeiba 2008, since it allows us to evoke briefly the role of PDC in transplantation and oral tolerance. However, we have not quoted the work of Irla (2010), since it deals with regulatory T cells and we focus our review on the innate immune functions of PDC.

5. Page 5 paragraph 2.4: when the authors discuss the role of pDC in diseases, they focus on autoimmune disorders, GVHD, atherosclerosis, and chronic viral infections but cancer was omitted. Yet, metabolic pathways are deeply altered in the context of cancer and I would assume that the innate functions of pDC would be modulated by the metabolic changes occurring in tumor microenvironment. This needs to be discussed.

This is a very interesting suggestion (please also refer to comment #1 of reviewer #1). Indeed, metabolism may play an important role in both tumor progression and antitumor immunity. Thus, a sentence has been added in the paragraph dealing with PDC ontogeny and localization, and different references describing PDC infiltrates in tumors have been quoted. We have quoted original works as advised by reviewers #3. Two small paragraphs have been added in the section called "2.4 Implications of PDC in diseases". Again, references have been added in this section, including original works and reviews on metabolism and cancer. Moreover, we have also evoked quickly in different parts of the revised version that the tumor microenvironment may impact on PDC metabolism.

6. Page 7: when the authors discuss the role of glycolysis on pDC functions upon TLR7 triggering, it is not clear whether this is a global regulation of the transcription or whether this is specific of genes related to type I IFN pathway.

Glycolysis after TLR7 triggering on human PDC seems necessary for most of the PDC innate immune functions (e.g., type I IFN, costimulatory molecules). However, the authors concentrated most of their work on type I IFN pathway. In the text, we wrote "2-DG inhibits the increase of *IFNA*, *CD80* and *CD86* mRNA induced by exposure to Flu⁴. This suggests that glycolysis induced by the TLR7 pathway regulates these genes at the transcriptional level.

7. Page 10: it is not very interesting but not clear to me how the massive decrease of intracellular cholesterol content is connected to the activation of STING/cGAS pathway leading to spontaneous type I IFN production in macrophages. This should be clarified.

This is true. The explanation provided in the first version of our manuscript was not clear. We have modified the sentence concerning this point.

8. The figures nicely support and illustrate the main text of the review. Nevertheless, I would suggest to add a table summarizing the main effects of each metabolic pathway on pDC biology by comparing human versus mouse and TLR7 versus TLR9 stimulation.

This is a very interesting suggestion. We have added a table summarizing the impact of pharmacological agents targeting the different metabolic pathways on TLR7/9 stimulation. Again, we focus on innate immune functions, including: type I IFN, IL-6 and TNF production as well as costimulatory molecule expression.

Competing Interests: No competing interests were declared.

Reviewer Report 05 May 2017

<https://doi.org/10.5256/f1000research.12232.r22503>

© 2017 Soumelis V et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Vassili Soumelis

Institut Curie, PSL Research University, Paris, France

Francois Xavier Danlos

Institut Curie, Paris, France

This review by Saas et al. reports on an original question, rarely addressed in reviews: the role of metabolism on the innate functions of plasmacytoid dendritic cells. Authors have performed a very good job summarizing current knowledge in the field. They very extensively present the molecular and functional pathways involved in PDC biology, and the possible interactions with various metabolic pathways. This way represents the current state-of-the-art. A large number of references are cited, in the field of general PDC biology, including important founder papers, as well as in the field of metabolism, and the role of metabolic pathways in PDC.

We only have a few comments on the manuscript:

1. The discussion of PDC implication in disease could be expanded. In particular, authors could discuss the role of PDC in the tumor microenvironment. It is known that metabolism plays an important role in tumor development and antitumor immunity. Can this also be through affecting PDCs? Is there a crosstalk between PDC biology, metabolism, and tumor progression? Several articles in the past few years have addressed the function of PDC in cancer and could serve as a basis for a discussion. Other diseases could also be discussed in more details, in particular autoimmunity. Indeed, the pathways involved in PDC activation in disease context may be slightly different from exogenous purified TLR ligands, due to the diversity of stimuli and the complexity of the inflammatory microenvironments.
2. Figure 2 is a bit too dense and confusing. We suggest to clarify it removing or reorganizing some of the information.
3. The article should also be edited for better English.

Is the topic of the review discussed comprehensively in the context of the current literature?

Yes

Are all factual statements correct and adequately supported by citations?

Yes

Is the review written in accessible language?

Partly

Are the conclusions drawn appropriate in the context of the current research literature?

Yes

Competing Interests: No competing interests were disclosed.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response (F1000Research Advisory Board Member) 15 Jun 2017

Philippe Saas, Inserm, UMR1098, Besançon, France

We thank the reviewers for their constructive comments. We appreciate greatly these comments and we have tried to answer to them. Please find below a point by point response to the reviewers' comments.

1. The discussion of PDC implication in disease could be expanded. In particular, authors could discuss the role of PDC in the tumor microenvironment. It is known that metabolism plays an important role in tumor development and antitumor immunity. Can this also be through affecting PDCs? Is there a crosstalk between PDC biology, metabolism, and tumor progression? Several articles in the past few years have addressed the function of PDC in cancer and could serve as a basis for a discussion. Other diseases could also be discussed in more details, in particular autoimmunity. Indeed, the pathways involved in PDC activation in disease context may be slightly different from exogenous purified TLR ligands, due to the diversity of stimuli and the complexity of the inflammatory microenvironments.

This is a very interesting suggestion (please also refer to comment #5 of reviewer #2). Indeed, metabolism may play an important role in both tumor progression and antitumor immunity. Thus, a sentence has been added in the paragraph dealing with PDC ontogeny and localization, and different references describing PDC infiltrates in tumors have been quoted. We have quoted original works as advised by reviewers #3. Two small paragraphs have been added in the section called "2.4 Implications of PDC in diseases". Again, references have been added in this section, including original works and reviews on metabolism and cancer. Moreover, we have also evoked quickly in different parts of the revised version that the tumor microenvironment may impact on PDC metabolism. However, to the best of our knowledge, no specific data are available today. We do not want to speculate too much on the impact of tumor microenvironment on PDC functions. We

have made no further comments on autoimmunity and the diversity of stimuli.

2. Figure 2 is a bit too dense and confusing. We suggest to clarify it removing or reorganizing some of the information.

We agree with this comment. We have simplified both panels A and B of Figure 2. In addition, we have modified a little bit the figure legend.

Competing Interests: No competing interests were declared.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research